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Technology Changes Drive Legal Changes for Antibody Patents:
What Patent Examiners Can Teach Courts About the Written
Description and Enablement Requirements1
S. Sean Tu2
Christopher M. Holman3
Abstract
Antibody patents form the basis of some of the most valuable
biotechnology products on the market. In 2020 alone, the sales of the top
three drugs exceed 10 billion dollars. Two of those three drugs are
monoclonal antibodies (Humira and Keytruda). In the past, patent law
offered broad protection for monoclonal antibodies. As time has progressed,
however, courts have narrowed the scope of antibody patents. However,
very little research has been done to see how patent examiners are applying
the rules of patentability to these valuable antibody patents.
We examine approximately two decades worth of antibody patents to
determine how the US Patent Office has dealt with antibody patents.
Specifically, we examine every patent directed to an antibody composition of
matter from 2001-present. We find that patent examiners have steadily
increased the use of 112(a) enablement and written description rejections
while slightly decreasing the use of anticipation and obviousness rejections.
Accordingly, these data suggest that 112(a) plays a greater role in policing
claim scope than prior art rejections, which is the most frequently used
rejection type for every other technology center. Correspondingly, patent
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applicants have also changed the type of claims they are drafting. Claims
have moved from broad claims based only on function to narrow claims
based on antibody structure.
We also find that the number of antibody composition patents has
dramatically increased, while the number of claims per patent has decreased.
Additionally, the number of words in each independent claim has increased
three-fold. These data present an interesting evolution for antibody patents
that mirrors the changing nature of antibody technology and offers some
insights for improving antibody patent prosecution.
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INTRODUCTION
Antibody patents are associated with some of the most
valuable drugs in the world. In 2020, two of the top three selling
drugs were monoclonal antibodies (Humira and Keytruda), bringing
in billions of dollars in sales. In 2016 alone, Humira generated $25.6
billion for AbbVie. As biologics overtake small molecules as the
world’s most valuable drugs, antibody patents play an increasingly
important role to drug companies, medical insurance companies as
well as consumers.
The evolution of antibody patents, however, has been one that
has dramatically shifted from the early 2000s to present. Previously,
antibody patents were granted broad genus type protection.
Currently, however, antibody patents usually cover narrow specific
antibodies that have well defined structures, especially when it
comes to the structural elements that define the specific binding
regions of the antibody.
This shift in scope has been proven by courts who have
recently been apt to invalidate claims with broad scope. For
example, the Federal Circuit just recently overturned a $1.1 billion
jury verdict on a biotechnology patent based on antibody type
technology, finding the asserted claims too broad and thus invalid
under the written description requirement.4
Changes in technology always move faster than changes to
the law. Courts are constantly playing a game of catch up to new
technological developments. In the patent realm there is an added
layer of review by the USPTO. Changes to USPTO policy occur even
slower than courts because the USPTO must respond to court
4

Juno therapeutics, Inc. v. Kite Pharma, Inc. (Fed. Cir. August 26, 2021)
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decisions, usually in the form of guidance documents and/or
examiner training materials. Accordingly, changes to patent policy
at the prosecution level should, in theory, lag slowly behind changes
in the law.
Surprisingly, our data show that patent examiners at the
USPTO have been independently applying a higher standard of
review for antibody patents even before the USPTO put out specific
guidance and much earlier than current Federal Circuit caselaw.
Specifically, patent examiners were increasingly using the
enablement and written description requirements for biotechnology
patents long before courts have been applying an enhanced 35 USC
112(a) requirement.
For most areas of technology, prior art rejections are the most
difficult hurdle that applicants must overcome to obtain a patent.
However, antibody patents face a very different challenge.
Specifically, lack of enablement and not meeting the written
description requirement seem to be the most difficult hurdles to
overcome for antibody composition of matter claims. These types of
challenges that are rare in most other technology areas are common
for antibody technologies.
We argue that the enhanced 112(a) standard applied by
examiners are keyed to changes in antibody technology and less
keyed towards changes in the law. As antibody technology changed
from being primarily used as a diagnostic tool to a therapeutic drug,
patent examiners quickly adjusted to the technology by rejecting
those broad antibody claims for lack of enablement and/or the
necessary written description requirements.
Most USPTO examiners do not have a legal background, but
all examiners are required to have a technical background. These
data support the idea that patent examiners are able to respond to
changes in technology well ahead of any formal guidance from the
PTO and the courts. By applying a stricter standard for written
description and enablement in response to changes in the
technology, patent examiners have narrowed antibody claims to give
exclusive rights to only those narrow claims that are supported by
the disclosure of the specification. In this way, although the claims
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are narrower, they also avoid invalidation via anticipation and
obviousness arguments.
In Part I, we discuss the databases that were created for this
study. In Part II we present our results. In Part III we present how
these results fit within 35 USC 112(a) jurisprudence. Finally, in Part
IV we offer policy recommendations and a critique the current state
of antibody patents based on our findings.
I. THE DATASETS
We created three unique datasets for this study. 5 The goal of
this study was to determine of antibody claims experience a different
prosecution history compared to other biotechnology patents.
A. The Antibody Dataset
The first dataset comprises of over 6,000 patents containing
antibody composition of matter patents (hereinafter antibody dataset).
These patents had filing dates ranging from November 29, 2000 to
June 1, 2021 and issue dates from June 18, 2002 to August 3, 2021.
Our initial search included every patent with the term
“antibody” within the claim (over 46,000 patents). However, after
reviewing the claims of numerous patents we determined that the
dataset was too broad for our purposes and included many patents
that were only tangentially related to antibodies. Accordingly, we
used a title search using the term “antibod$” which resulted in
S. Sean Tu’s pertinent credentials are: B.S. in Microbiology and B.S. in
Chemistry, University of Florida; Ph.D. in Pharmacology, Cornell
University; Post-Doctoral Fellow, La Jolla Institute for Allergy and
Immunology; Associate with Foley & Lardner (Chemical, Biotechnology &
Pharmaceutical Practice/Life Science and Nanotechnology Industry Team).
5

Christopher Holman’s pertinent credentials are: B.A. in Chemistry,
California State University, Hayward; Ph.D. in Biochemistry and Molecular
Biology, University of California, Davis; Post-Doctoral Fellow, Syntex
Research/Roche Bioscience; Patent Agent with Flehr Hohbach, LLP.;
Associate with Pennie & Edmonds, LLP.; Associate Patent Counsel with
Transgenomic, Inc.; Patent Counsel with Maxygen, Inc.; Vice-President,
Intellectual Property with PhyNexus, Inc.
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15,285 patents. We then reviewed the titles of these patents to
determine if the patents truly represented antibody composition of
matter type subject matter. After reviewing these 15,285 and after
liberally removing those patents not related to antibody composition
of matter claims, we were left with 6,407 patents. To ensure
consistent coding a sample of 400 patents were taken and reviewed
by both authors. This review resulted in over 90% consistency.
These data represent mainly antibody composition of matter
claims. Specifically, we attempted to eliminate those patents with
only claims directed to drug conjugates, pharmaceutical
compositions, methods of use, treatment claims, antibody libraries,
polyclonal antibodies, transgenic mice used to produce antibodies,
kits with antibodies and expression vectors. We retained patents
directed towards: antibodies of any isotype (IgE, IgA, IgD, etc.),
humanized and chimeric antibodies, bispecific antibodies, antibody
fragments, nucleic acids encoding specific antibodies, neutralizing
antibodies, engineered antibodies, and recombinant antibodies.
All the data has been grouped by the first office action date. This
metric is better than the filing date because prosecution dates can
change dependent on the examiner’s docket and the backlog of
patents at the patent office. Accordingly, filing dates can be
deceptive because examiners may not pick up the application for
long periods of time after the PTO receives the application. For
example, US Patent No. 6,770,466 has a filing date of July 18, 2001.
However, the first office action did not occur until June 12, 2003,
about two years after the filing date. Therefore, using the first action
date better represents the state of the law at the time the application
was under review by the PTO.
B. The 1650 Control Group Dataset
A second data set was generated to act as a control group
(hereinafter 1650 control group). This dataset consisted of over 92,000
patents from Workgroup 1650.6 The 1650 control group includes
As shown in Section II(C) below, most antibody patents come from
Workgroup 1640. Workgroup 1650 was chosen as a control group because
this workgroup encompasses patents directed to “Fermentation,
Microbiology, Isolated and Recombinant Proteins/Enzymes.” Workgroup
6

Electronic copy available at: https://ssrn.com/abstract=4025167

6

Orange Book Patent Prosecution and Litigation

[2-Feb-22

patents directed towards “isolated and recombinant
proteins/enzymes.”
Workgroup 1650 was chosen as a control because many of the
characteristics of the patents found in workgroup 1640 (the
workgroup associated with most antibody patents) could also be
found in 1650. For example, many of the traits found in recombinant
proteins and recombinant enzymes will be similar for antibody
claims. For example, recombinant enzymes exhibit functional
attributes that are tied to specific structural elements. Similarly,
therapeutic antibodies exhibit functional characteristics based on the
specific antibody Complementarity Determining Regions (CDRs).7
Additionally, only nine of the 6,408 antibody patents were found in
workgroup 1650, so the overlap between these two datasets is
minimal.
Similar to the antibody dataset, the 1650 control group was
organized chronologically by the first action date.
C. The Claim Type Dataset
A third data set was generated to examine claim type
(hereinafter claim type dataset). We sampled 340 independent patent
claims from the antibody dataset. We reviewed 20 independent
claims (Claim 1) from each year from 2002-2018. We determined if
the antibody claim type was directed to an antibody as described: (1)
by binding to a specific antigen (and giving the antigen description /
epitope) or (2) structurally by its binding site or specific heavy chain
/ light chain sequences. Structural limitations were most frequently
described as specific sequence identification numbers (SEQ ID).
These SEQ ID numbers corresponded to either specific amino acid
sequences or specific nucleotide sequences, usually corresponding to
specific CDR regions.
Antibody claims can be very broad (based only on the
description of the antigen) to fairly narrow (based on specific
1650 contains many of the same types of issues present in Workgroup 1640,
which is directed to “Immunology, Receptor/Ligands, Cytokines
Recombinant Hormones, and Molecular Biology.”
7

For a deeper discussion of CDRs, see Appendix 1.
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binding regions of the antibody along with a description of the
antibody’s function). In general, antibodies can be defined by: (1)
reference to the target antigen; (2) the epitope; (3) target antigen and
further antibody functional features; (4) antibody and structural
features; (5) their own structure (amino acid sequences); (6) antibody
nucleic acid sequences encoding the antibody; (7) the antibody
production process; and/or the hybridoma producing antibody. In
general, this list is ordered from broadest to narrowest type of
antibody claims.
The broadest patents usually claim antibodies by only
referencing the target antigen, without reciting any structural
elements for the antibody.8 In contrast, the narrowest claims
reference only the hybridoma that is used to produce the specific
antibody, thus giving the complete antibody structure and the means
to produce the antibody.9 In the claim type dataset, we consolidate
antibody definitions 1-3 together (antibody defined by antigen
structure and no antibody structure) and 4-7 together (antibody
defined by its own structure).
D. Data Limitations
Because we are working with issued patents, there is a
selection issue for recently granted patents with first office action
dates of 2019, 2020 or 2021. Specifically, recently filed patents will
always have much shorter prosecution histories simply because they
have been reviewed by the PTO and issued very recently. Thus,
many of these patents have prosecution histories that are not
representative of most patents. Specifically, these patents usually
come from large patent families which exhibit anomalous
prosecution histories. To minimize this selection effect we have
excluded all patents with first actions that occurred after 2019.
8
An example of this broad claim would be, “An antibody that specifically binds
X”. See, for example, US Patent No. 7060800.
9
An example of this narrow claim would be, “A hybridoma cell line deposited
as ATCC Accession Number X.” See for example, US Patent No. 7,547,544. The
hybridoma cell line claims are usually the least valuable to firms because they are
easy to design around. Specifically, if a competitor develops an independent
hybridoma cell line, even if the competitor’s hybridoma cell line produces a very
similar mAb to the patented hybridoma cell line, it will not infringe the patented
cell line.
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II. RESULTS
First, we find that antibody patents experience many more
112(a) rejections compared to similar technology. Second, we find
that antibody claims have shifted from broad functional claims
defined by the antigen to narrower claims defined by the antibody
structure. Third, there was a five-fold increase in the number
antibody patents granted with a significant decrease in the number
of independent claims per patent. Finally, the number of words per
independent claim has also increased from 2002-2018, which also
suggests a narrowing of antibody claims over time.
A. Changes in Antibody Claims
Antibody claims and the rejections that patent examiners
apply to allow those claims has shifted dramatically from 2002-2018.
Three areas of greatest changes are: (1) increased use of 112(a)
rejections, (2) forcing applicants to narrow their claims by requiring
structural elements that define the antibody, thus changing the type
of antibody claim from claims that are defined only by the antigen’s
structure to claims that are defined by the antibody’s structure, and
(3) increased number of words necessary to claim the invention.
1. Increased Number of Written Description / Enablement Rejections
Patent examiners for antibody technology have dramatically
increased their use of the written description and enablement
rejection. Figure 1A10 shows that from 2003-2006 antibody patents
initially received 112(a) rejections only about 20% of the time and
almost doubles to 40% by 2018.11
A 20% rejection rate based on 112(a) is typical of biotechnology
patents. As shown in Figure 1B, the 1650 control group does not
10
These data have been segmented to show the percentage of office actions with specific
types of rejections for: (1) first office actions, (2) non-final office actions, and (3) final office
actions.
11
35 U.S.C. 112(a) rejections include both written description and enablement
rejections. These two rejections have been cojoined because examiners often confuse /
conflate these two doctrines even though they are separate and distinct requirements. See
Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010).
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show a discernable increase in 112(a) rejections over the same time
period. Accordingly, examiners in the 1650 control group only use
112(a) rejections in the 1650 control group about 20% throughout
2002-present.
Figure 1A

Figure 1B

2. Change in Type of Claims
The way antibody claims are drafted has also dramatically
changed from 2003 to 2019.12 As shown in Figure 2, in the early
2000’s approximately 70% of the claims were directed to antibodies
12

These data were based on the 340 patents from the Claim Type Dataset described in
Section I(B).
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that were defined only by their antigen or antigen binding site, while
about only 30% were defined by structural elements (usually given
by the exact amino acid sequence of the six CDRs or the full light
chain/heavy chain sequence). By 2011 we saw almost a complete
switch. In 2011, almost no antibody claims were characterized only
by their antigen binding site, and by the late 2010’s, almost 100% of
the claims were completely defined by their structural elements.
Figure 2

This change in the types of antibody claims allowed by
examiners corresponds to the increase in the number of words in
each claim13 as well as the increased use of 112(a) rejections.14
Currently patent examiners do not allow broad antibody claims
described only by the antigen. Thus, antibody patents are much
narrower because applicants must describe specific structures that
correspond to the antibody they are attempting to claim and can no
longer claim antibodies based solely on their antigen structure.
3. Increase in the Number of Words Per Independent Claim
In response to the increase in 112(a) rejections, applicants
have been adding words to their claims. As shown in Figure 3A, the
13
14

See Section II(A)(3) below.
See Section II(A)(1) supra.
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number of words in each independent claim has almost tripled from
2002 to 2018.15 Specifically, the number of words in each
independent claim increased from approximately 60 words per
independent claim in 2002 to over 160 words per claim in 2018. In
comparison, as shown in Figure 3B, the number of words in each
independent claim for the 1650 control group did not change that
much, only growing from approximately 100 words per claim in
2002 to about 120 words per claim in 2018.
Figure 3A

Figure 3B

15

These data were based on the 6,407 patents from the Antibody Dataset described in
Section I(A).
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B. Antibody Patent Rejections
Antibody patents differ not only from other patents in Technology
Center 1600 (TC 1600), but they differ from many other technology types.
We compare antibodies against all other technology centers. Additionally,
we review how examiners use prior art rejections against antibody patents.
1. Antibody Claims in Comparison to Other Technologies
The prosecution histories and rejections used for antibody
claims are different from almost every other Technology Center.16
We compared antibody patents with a first office action in 2018
against patents from all other technology centers. Figure 4 shows
that antibody patents do not receive many anticipation (35 U.S.C.
§102) or obviousness (35 U.S.C. §103) rejections compared to any
other Technology Centers (TC).17 Furthermore, antibody patents
receive fewer indefiniteness rejections (35 U.S.C. §112(b)) compared
to TC 1600, 1700, 3600 and 3700. Finally, antibody patents receive the
highest number of enablement and written description rejections (35
U.S.C. §112(a)) with about four times as many rejections as the next
highest TC.
These data show that 112(a) is the biggest hurdle to overcome
antibody patents. This is surprising because for every other
technology group, obviousness is the principal obstacle to receiving
a patent.
Figure 4

16

Technology Center 1600 includes all patents except those from Workgroup 1640.
Workgroup 1640 was excluded out because most antibody patents come from Workgroup
1640, which significantly skewed the results. See Section II (Figure 5, showing the
distribution of all antibody composition of matter patents). For example, Workgroup 1640
alone represents 24% of all 35 U.S.C. §112(a) rejections from Technology Center 1600.
17
TC 1600 Biotechnology and Organic Chemistry; TC 1700: Chemical and Materials
Engineering; TC 2100 Computer Architecture, Software, and Information Security; TC 2400
Computer Networks, Multiplex Communication, Video Distribution and Security; TC 2600
Communications; TC 2800 Semiconductors, Electrical and Optical Systems and
Components; TC 3600 Transportation, Construction, Electronic Commerce, Agriculture,
National Security and License & Review; TC 3700 Mechanical Engineering, Manufacturing,
Products; TC 4000 Training Academy.
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2. Other Substantive Rejections and Antibody Patents
Interestingly, as shown in Table 1 and Figure 4, antibody
patents do not regularly encounter prior art rejections. Specifically,
as shown in Table 1, obviousness rejections (35 U.S.C. § 103) in the
1650 control group steadily increase to about twice the number
found in the antibody group. A smaller but similar increase is seen
for novelty rejections (35 U.S.C. § 102).
When compared to other patents from other technologies,
antibody patents face substantially fewer prior art rejections. Other
patents in Technology Center 1600, which examines patent
applications in the fields of biotechnology and organic chemistry,
face obviousness rejections approximately five times more
frequently than antibody patents (Figure 4). This is significant
because prior art rejections are usually the most difficult rejections to
overcome during prosecution.18
Table 119
102Antibody
Patents
2002 0.093

1021650
Control
0.085

103Antibody
Patents
0.067

1031650
Control
0.072

18

S. Sean Tu, Patenting Fast and Slow: Examiner and Applicant Use of Prior Art, 38
Cardozo Arts and Entertainment Law Journal 101 (2020).
19
First Office Actions only. These results, however, are similar for non-final as well as
Final Office Actions.
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2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
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0.127
0.143
0.129
0.155
0.199
0.192
0.233
0.190
0.189
0.220
0.239
0.208
0.218
0.202
0.174
0.148

0.190
0.206
0.203
0.186
0.185
0.179
0.199
0.208
0.207
0.225
0.207
0.202
0.209
0.202
0.222
0.237

0.121
0.092
0.079
0.99
0.104
0.118
0.119
0.108
0.132
0.142
0.151
0.108
0.137
0.140
0.121
0.086

[2-Feb-22

0.159
0.152
0.162
0.156
0.158
0.173
0.196
0.216
0.234
0.266
0.264
0.254
0.256
0.265
0.285
0.301

Finally, as shown in Table 2, antibody patents and the 1650
control group encounter indefiniteness (35 U.S.C. § 112(b)) and
obviousness-type double patenting (ODP) rejections (35 U.S.C. § 101)
at approximately the same rates. These data are unsurprising
because both antibody patents and 1650 control patents have fewer
claims with an increasing number of patents filed per year (Figure
6A and Figure 7A). The ODP rejection data suggest that applicants
are filing more patents relating to the same product, which seems to
be a common strategy in this sector.20
Table 221
112(b)Antibody
Patents
2002 0.107
2003 0.173

112(b)1650
Control
0.095
0.242

ODPAntibody
Patents
0.013
0.058

ODP1650
Control
0.019
0.056

20
S. Sean Tu and Mark A. Lemley, What Litigators Can Teach the Patent Office About
Pharmaceutical Patents, Washington University Law Review (in press)(2021)(showing that,
for litigated Orange Book patents, pharmaceutical firms file numerous “secondary” patents
directed towards the same product, and that the obviousness type double patenting rejection
is one of the most common rejections found for these types of patents).
21
First Office Actions only. These results, however, are similar for non-final as well as
Final Office Actions.
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2016
2017
2018
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0.211
0.176
0.184
0.178
0.192
0.183
0.201
0.231
0.218
0.205
0.225
0.233
0.261
0.225
0.244

0.258
0.216
0.216
0.202
0.195
0.219
0.232
0.228
0.246
0.226
0.228
0.211
0.215
0.246
0.267

0.027
0.035
0.102
0.083
0.071
0.119
0.135
0.105
0.126
0.171
0.173
0.177
0.187
0.153
0.180

15

0.069
0.071
0.070
0.076
0.092
0.109
0.121
0.119
0.132
0.114
0.133
0.133
0.146
0.151
0.182

C. Changes with Antibody Patent Prosecution Practice
There have also been several important changes in
prosecution practice that have also evolved in the past two decades.
First, applicants have increased the number of antibody patents they
are filing over time. Second, there has been a decrease in the number
independent claims per patent over time. Finally, antibody patents
are going through prosecution faster than their older counterparts.
As an initial matter 98% of the antibody patents were found in
workgroup 1640. Specifically, Figure 5 shows that art units 1643 and
1644 contained the lion’s share of antibody patents. Patents in
workgroup 1640, are directed to “Immunology, Receptor/Ligands,
Cytokines Recombinant Hormones, and Molecular Biology.” Art
Units 1643 and 1644 include inventions directed to “peptides or
proteins, ligands or reaction products thereof” and “drug, bioaffecting and body treating compositions.”
Figure 5
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1. Increasing Number of Antibody Patents
Figure 6A shows that the number of antibody composition of
matter patents has steadily risen from only about 100 granted with a
first office action date in 2002 to a steady state of over approximately
500 antibody patents in 2018.22 Unsurprisingly, as antibodies became
increasingly used as therapeutics, and therefore more valuable, more
firms moved towards the patent system to protect their inventions.
There is a similar increase in the absolute number of patents in the
1650 control group. However, in the 1650 control group we only see
a two-fold increase in the number of patents, while there is a fivefold increase in the antibody group.
Figure 6A

Figure 6B

22

These data were based on the 6,407 patents from the Antibody Dataset described in
Section I(A).
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2. Fewer Claims Over Time
As shown in Figure 7A, the number of independent claims in
those patents has decreased from an average of about 3.5 claims in
2002 to just over 2 claims in 2018.23 Thus, currently more patents are
being granted with fewer independent claims. As shown in Figure
7B, we note that the number of independent claims also are reduced
in the 1650 control group, however, the magnitude of the change is
less dramatic, moving from approximately 2.5 independent claims in
2002 to just over 1.5 independent claims in 2018.
Figure 7A

Figure 7B

23

These data were based on the 6,407 patents from the Antibody Dataset described in
Section I(A).
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3. Fewer Original Patent Filings Over Time Compared to the 1650 Control
As shown in Figure 8A, more “original” patents were granted
over time.24 An “original” patent is defined as a patent that does not
claim priority to another patent. Specifically, in 2002-2005 only
approximately 30% of granted patents were original filings.
However, by 2009-2018 the number of granted patents that were
original filings increased to about 50%. In contrast, both divisional
(DIV) and continuation (CON) patents, for the most part, stayed at
approximately 20-25% while continuation-in-part (CIP) patents
stayed at around 5% throughout 2006-2018.
In contrast, Figure 8B shows that, for the 1650 control, the
number of granted patents that were original filings stayed at
around 60% through 2002-2018. Additionally, DIVs and CONs
stayed at around 15-20% while CIPs also stayed at around 5%.
Figure 8A

24

These data were based on the 6,407 patents from the Antibody Dataset described in
Section I(A).
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Figure 8B

Table 3 shows the overall data where the data is not
segmented by year. Additionally, Table 3 includes the percentage of
applications with restriction requirements. These data show that
antibody patents claim priority to another application and have
fewer original patents compared to the 1650 control group. Although
the antibody dataset has more divisional patents, they experience
about the same number of restriction requirements as the 1650
control group.
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Table 3
Antibody
Dataset
25
Continuing Applications
52%
Continuation-in-Part Patents 3%
Continuation Patents
25%
Divisional Patents
24%
Original Patents
48%
Restriction Requirements
67%

1650 Control
41%
5%
20%
16%
59%
63%

4. Shorter Patent Prosecution Duration Over Time
The patent prosecution profile has also changed for antibody
patents over time. First, as shown in Figure 9A, the number of office
actions per patent has decreased from approximately 2.5 in the early
2000’s to only 1.2 office actions per patent in 2016-2018. In contrast,
as shown in Figure 9B, the number of office actions in the 1650
control group remains relatively steady at 1.8 office actions per
patent throughout the 2002-2018 timeframe.26 Thus, the back-andforth negotiations between the examiner and the applicant for
antibody patents are far fewer now than two decades ago.
Figure 9A

25
A “continuing application” is a continuation, divisional, or continuation-in-part
application. See also MPEP §201.02.
26
The number of Office Actions per Grant corresponds to the Office Action per Grant
Ration (OGR score). See S. Sean Tu, Three New Metrics for Patent Examiner Activity:
Office Action per Grant Ratio (OGR), Office Actions per Disposal Ratio (ODR), and Grant
Examiner Ratio (GER), 100 Journal of the Patent and Trademark Office Society 277 (2018);
S. Sean Tu, Bigger and Better Patent Examiner Statistics. 59 IDEA 309 (2018).
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Figure 9B

This naturally corresponds to the duration of prosecution.
Figure 10A shows that in the early 2000’s patent prosecution would
customarily take about 2.5 years and fell to about only 1.2 years from
2016-2018. There is a similar decrease in patent prosecution duration
in the 1650 control group, shown in Figure 10B. However, the
magnitude of this decrease is much smaller, moving from about 1.8
years to 1.5 years.
Figure 10A

Figure 10B
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III. DISCUSSION
The caselaw around antibody patents, specifically around the
written description and enablement requirements, has evolved in the
past two decades.27 The PTO has attempted to track the changes in
caselaw with their own guidance around antibody patents. In this
section, we interpret the empirical results by placing these results in
the context of the time-dependent PTO policy and Federal Circuit
caselaw on antibody patents.28
A. Change in Claim Type
The increase in 112(a) rejections faced during prosecution
supports the idea espoused by Judge Lourie, specifically that “[w]hat
is new today is not the law, but generic claims to biological materials
that are not fully enabled.”29 These data are also consistent with
27

See S. Sean Tu and Christopher Holman, Antibody Claims and the Evolution of the
Written Description and Enablement Requirement, IDEA (in press, 2022) for a complete
discussion of the historical changes in PTO policy and Federal Circuit jurisprudence on
antibody patents.
28
See S. Sean Tu and Christopher Holman, Antibody Claims and the Evolution of the
Written Description and Enablement Requirement, IDEA (in press, 2022) for a complete
discussion of the historical changes in PTO policy and Federal Circuit jurisprudence on
antibody patents.
29
Amgen Inc. v. Sanofi, Aventisub LLC, 850 F. App'x 794, 795 (Fed. Cir. 2021) (also
stating that, “in order to have invented a genus, one needs to have invented species that
constitute the genus. Drawing a broad fence around subject matter, without filling in the
holes, is not inventing the genus. It in fact discourages invention by others. If one has
disclosed or enabled only a small number of invented species, then one has not invented a
broad genus. Invention of a genus means to conceive and reduce to practice a reasonable
number and distribution of species constituting the genus. Mere statement of a genus does
not demonstrate that one has invented a generic concept, without the enablement of
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findings by other commentators that non-ANDA pharmaceutical
patents face higher invalidation rates based on 112(a) during
litigation.30
Applicants have changed from broad genus claims defined by
the antigen alone to narrower claims defined by the antibody’s own
structure (Figure 2). Below we describe the evolution of these claims
and develop a hypothesis of how the changing nature and uses for
antibodies resulted a shift in antibody claiming practice.
1. Early Antibody Claims: Antibody Claims Defined by Antigen Structure
Only
During this period monoclonal antibodies were mainly used
as research and diagnostic tools and not as therapeutic agents. These
mouse antibodies were only used to determine if an antigen was
present or absent, it did not matter where the antibody bound, i.e.,
what the specific epitope was, nor the type of antibody, it only
mattered if the antibody bound the antigen or did not bind to the
antigen.
This binary decision (binding vs. not binding) was consistent
with broad patent protection based on antigen structure alone
because, during this time period, the value of the antibody rested
primarily in the antibody’s ability to bind and detect the antigen.
Accordingly, during this early phase in monoclonal antibody
development, an applicant could receive a patent by simply
characterizing the antigen (without giving any structural elements of
the antibody itself). 31

constituent species.”)
30
John R. Allison & Lisa Larrimore Ouellette, How Courts Adjudicate Patent
Definiteness and Disclosure, 65 Duke Law Journal 609, 666 (2016) (Table 7 showing that
non-ANDA pharmaceutical patents are the worst performers on written description of any
industry); see also Jackob S. Sherkow, Describing Drugs: A Response to Professors Allison
and Ouellette, 65 Duke Law Journal 127, 128 (2016). Cf. Dmitry Karshtedt, Mark A.
Lemley, and Sean B. Seymore, The Death of a Genus Claim, 35 Harvard Journal of Law and
Technology (in press 2021) (showing that only a small minority of Federal Circuit decisions
have upheld a genus claim in the chemical industry over the past thirty years).
31
S. Sean Tu and Christopher Holman, Antibody Claims and the Evolution of the Written
Description and Enablement Requirement, IDEA (in press, 2022); see also PTO Written
Description Training Materials 2008 revisions, Example 13. 66 Fed. Reg. at 1106 (2001).
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As shown in Figure 1, during this early stage, 112(a) was not
used frequently to reject antibody patents. Additionally, as shown in
Figure 2, during this time period the majority of these antibodies
were claimed by describing only the antigen. These genus claims
did not define the antibody structurally, but instead by antigen that
the antibody could bind to specifically. The patentee was only
required to disclose the antigen’s structure. The resulting broad
scope of antibody claims made sense during this period of antibody
development because antibodies were being used primarily as
research or diagnostic tools.
Example 1 is typical of an antibody patent during this
timeframe. No antibody structure is given in the ‘800 patent. The
antibody is only defined by the antigen (SEQ ID NO: 9). This claim
is relatively short (only eighteen words) because it defines the
antibody only by the antigen that it binds.
Example 1- US Patent No. 7,060,800
Claim 1: An isolated antibody or antigen binding
fragment thereof, which specifically binds to a
polypeptide of SEQ ID NO:9.32
2. Replacing Broad Genus Claims: Antibody Claims Defined by Antibody
Complementarity Determining Regions (CDRs)
During this period monoclonal antibodies began to be used as
therapeutic agents, however they faced many issues due to the
human anti-mouse antibody (HAMA) response.33 Accordingly,
these early therapeutics suffered major setbacks at the FDA and
often times did not work well as human medicines.34
The PTO and courts narrowed claims due to the new
therapeutic uses for antibodies as well as the realization that binding
to different epitopes could have dramatically different functional
32

SEQ ID NO:9 is a human TNF-x protein that is 228 amino acids.
These negative effects are based on the fact that the human body recognizes the mouse
antibody as foreign; see also Appendix 1 for deeper discussion of HAMA response.
34
See for example, Nadim Mahmud, Dusko Klipa, and Nasimul Ahsan, Antibody
Immunosuppressive Therapy in Solid-Organ Transplant, 156 mAbs 148, 151
(2010)(showing that OKT3’s “adverse effects proved to be consistently problematic.”).
33
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effects on the body. Courts began to apply a stricter version of the
Lilly written description requirement requiring applicants to describe
their antibodies using structure instead of function.35 Antibody
claims changed as the PTO and courts began to reject and invalidate
claims based only on antigen structure. Accordingly, during this
time period examiners began using 112(a) more frequently to reject
antibody claims that were directed towards genus claims and started
forcing applicants to define antibody structures.
In response to these rejections, applicants moved towards
claims that specifically defined the antibody based on structural
elements.36 These claims usually focused on the CDRs, which are the
antibody structural elements that define the binding site of the
antibody to antigen.37 There are six CDRs for each antigen receptor
that can come into contact with the antigen. Each CDR binding site
is usually defined by 3-15 amino acids. Thus many antibody claims
during this time period require at least 50-60 amino acids spread
among the 6 CDRs (usually 6 individual SEQ IDs).
Example 2 is a typical antibody claim during this timeframe.
The antibody CDRs are now given as the key structural elements
that define the invention. These CDRs, however, are based on
relatively short amino acid sequences. Accordingly, even with
defined CDR structural elements, these antibody claims still can be
broad.
Example 2- US Patent No. 9,353,181
Claim 1: An isolated IL-23p19 antibody, comprising a
light chain variable region and a heavy chain variable
region, said light chain variable region comprising:
a complementarity determining region light chain 1
(CDRL1) amino acid sequence of SEQ ID NO:50;
a CDRL2 amino acid sequence of SEQ ID NO:56; and
a CDRL3 amino acid sequence of SEQ ID NO:73,
35

Christopher M. Holman, Is Lilly Written Description a Paper Tiger: A Comprehensive
Assessment of the Impact of Eli Lilly and Its Progeny in the Courts and PTO, 17 Alb. L.J.
Sci. & Tech. 1 (2007).
36
See Figure 2.
37
CDRs are the crucial antibody structural elements that confer antibody
specificity. See also Appendix 1 for Antibody Technology primer.
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said heavy chain variable region comprising:
a complementarity determining region heavy chain 1
(CDRH1) amino acid sequence of SEQ ID NO:5;
a CDRH2 amino acid sequence of SEQ ID NO:28; and
a CDRH3 amino acid sequence of SEQ ID NO:44.38
3. Narrow Species Claims: Antibody Claims Defined by Complete Antibody
Structure
Presently, many antibodies are defined by both their variable
and framework regions. Accordingly, most antibody claims
currently include an almost complete description of the entire
antibody structure, and not just the CDR regions.
The current state of monoclonal antibody technology relies on
chimeric antibodies and antibody “humanization“ to overcome the
deleterious effects of the HAMA response. By using recombinant
DNA, scientists can now create an antibody that is mostly (or
entirely) human. These chimeric and humanized antibodies are used
for therapeutic purposes. Thus, for humanized antibodies both the
CDR structure as well as the framework structures are important.
Unlike previous antibody iterations, however, the DNA structures
are known for humanized antibodies. Accordingly, the primary
structure of these antibodies can be well defined.
Example 3 is a typical antibody claim during this timeframe.
The claim contains an almost complete antibody structure. Both the
heavy and light chains are structurally defined. Additionally, the
amino acid sequences given are between 112-122 amino acids long.
Furthermore, this antibody has the functional requirement of being
“neutralizing.” Thus, these claims are much narrower because the
structure of antibody is defined with much more specificity and
includes additional functional requirements.
Example 3- US Patent No. 10,822,397
Claim 1: An isolated antibody or epitope-binding
fragment thereof that specifically binds to at least one
38

SEQ ID NOs 50, 56, 73, 5, 28 and 44 are 14, 7, 11, 5, 17, and 8 amino acids in length,
respectively.
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conformational (non-linear) epitope of enterovirus 71
(EV71), wherein the antibody comprises at least one
variable light chain and at least one variable heavy
chain, wherein the variable light chain comprises an
amino acid sequence comprising the amino acid
sequence set forth in SEQ ID NO: 3, and wherein the
variable heavy chain comprises an amino acid
sequence comprising the amino acid sequence set
forth in SEQ ID NO: 4 or SEQ ID NO: 5, wherein the
antibody or epitope-binding fragment thereof is
neutralizing.39
B. Increasing Use of 112(a)
We find that antibody examiners have increased the use of
112(a) to reject antibody patents since 2006 (Figure 1A).40
Additionally, 112(a) is the major hurdle that applicants must
overcome before receiving an antibody patent (Figure 4).41
Beginning in 2006, patent examiners were ignoring their own
PTO written description guidelines by increasingly applying a more
stringent 112(a) standard.42 This more stringent standard was being
applied even when courts had specifically upheld the PTO’s written
description antibody guidelines.43
39

SEQ ID NOs 3, 4 and 5 are 112, 122, and 119 are amino acids in length, respectively.
See Figure 1A (showing an almost 100% increase in the use of 112(a) from 2006
to 2018).
41
See Figure 4 (showing that antibody patents experience 10-fold more 112(a) rejections
compared with any other technology center. Additionally showing that 112(a) is the major
obstacle to obtaining an antibody patent compared with other technology centers where 103
rejections are the primary obstacle.)
42
Written Description Training Material, Revision 1, March 25, 2008. (Example 13,
showing that a claim directed towards “An isolated antibody capable of binding to antigen
X” can satisfy the written description requirements of 35 U.S.C. §112); we note that our data
does not distinguish between the written description or enablement guidelines. However,
this is consistent with the 2008 written description guidelines put out by the PTO because it
would be illogical to put out a guidance that gives an example that satisfies the written
description requirement while simultaneously failing the enablement requirement (without
specifically stating that in the guidelines).
43
See Enzo Biochem v. Gen-Probe, Inc., 323 F.3d 956, 964 (Fed.Cir. 2002) (stating
“[we] are persuaded by the Guidelines on this point and adopt the PTO’s applicable standard
for determining compliance with the written description requirement.”); Noelle v. Lederman,
355 F.3d 1343, 1349 (Fed. Cir. 2004)(in holding no interference-in-fact “[t]he court adopted
the USPTO Guidelines as persuasive authority for the proposition that a claim directed to
40
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We argue that patent examiners were able to look beyond
caselaw and consider the intent of 112(a) through the lens of how the
technology was being used. Accordingly, patent examiners from
2006-2018 were applying 112(a) in a manner that was contrary to the
PTO training materials.44 Interestingly, both the courts and the PTO
ended up concurring with patent examiners, however this
concurrence took over a decade and came once the issue was
squarely before the court.
Why have patent examiners been applying a different
standard than what was expected from the PTO training guidelines
and legal precedent? We believe it is because examiners were
following the science and advances in antibody technology. Patent
examiners are trained scientists and not trained lawyers.45 We find
that in Technology Center 1600, 30% of examiners have masters
degrees and 62% have Ph.D.s in some natural science degree.46 In
contrast, most examiners do not have a traditional legal education,
with only approximately 15% having a J.D.47
By 2018, the PTO ended up conforming with examiners and
repealing its previous guidance stating that, “[Example 13 of the
‘any antibody which is capable of binding to antigen X’ would have sufficient support in a
written description that disclosed ‘fully characterized antigens.’”); Centorcor Ortho Biotech,
Inc. v. Abbott Labs, 636 F.3d 1341, 1351-2 (2011)(stating that “an applicant can claim an
antibody to novel protein X without describing the antibody when (1) the applicant fully
discloses the novel protein and (2) generating the claimed antibody is so routine that
possessing the protein places the applicant in possession of an antibody.”).
44
Written Description Training Material, Revision 1, March 25, 2008 (repealed in
2018).
45
All examiners are required to have a science degree in their field. Accordingly, 100%
of patent examiners will have a Bachelor of Science degree, however, many examiners have
also obtained graduate degrees. See also, https://www.uspto.gov/jobs/become-patentexaminer (visited November 21, 2021).
46
See also S. Sean Tu, Paul R. Gugliuzza, and Amy Semset, Overqualified and
Underrepresented: Gender Inequality in the Pharmaceutical Patent Field, (in manuscript,
2022)(Table 2, showing the different education levels of examiners. Showing that the
majority of examiners in 1600 have doctorate degrees, while about 15% have juris doctorate
degrees).
47
See also S. Sean Tu, Paul R. Gugliuzza, and Amy Semset, Overqualified and
Underrepresented: Gender Inequality in the Pharmaceutical Patent Field, (in manuscript,
2022)(Table 2, showing the different education levels of examiners. Showing that the
majority of examiners in 1600 have doctorate degrees, while less than 15% have juris
doctorate degrees). Examiners are trained extensively in patent law during their first six
months in the PTO training academy.
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2008 Written Description Training Materials]…should not be used in
determining whether there is adequate written description under 35
U.S.C. §112(a) for a claim drawn to an antibody.”48 Although it took
over a decade for the courts and PTO to catch up with patent
examiners, both the Federal Circuit and the PTO now espouse the
same standards that patent examiners were applying for over a
decade.
C. Narrowing Claim Scope
The number of words in each claim is important because
previous studies have shown that increasing word counts in a claim
correlates with narrower scope.49 We find a three-fold increase in
the number of words in independent claims for antibody patents.
Specifically, there was an increase from 60 to approximately 180
words per independent claim. (Figure 3A) This is unsurprising
because the most common ways to traverse a 112(a) rejection is to
simply make claim amendments.50 Claim amendments almost
always require the applicant to add words.
These data also match the general trends that we identify
where patent examiners initially allowed broad claims in the early
development of antibody technology (which requires few words)
and then changing to only allow narrow claims as therapeutic
antibodies were developed (which requires many more words to
describe all six CDRs or the complete heavy and light chains). For
instance, Example 1 is relatively short and has only eighteen words.
In contrast, Examples 2 and 3 have five times more words with 96
and 97 words respectively. The increase in the number of words
combined with the fact that antibodies are now being defined by

48

USPTO February 22, 2018 memo from Robert W. Bahr, Deputy Commissioner for
Patent Examination Policy, “Clarification of Written description Guidance for Claims Drawn
to Antibodies and Status of 2008 Training Materials.”
49
Jeffrey M. Kuhn and Neil Thompson, How to Measure and Draw Causal Inferences
with Patent Scope, 26 International Journal of the Economics of Business 5 at 6
(2019)(showing that “a patent’s scope can be measured by counting the number of words in
its first claim, with more words corresponding to less scope.”).
50
S. Sean Tu, Patenting Fast and Slow: Examiner Rejections and Applicant Traversals
to Nonprior Art Rejections, 2021 Mich. St. L. Rev 411 (2021) (Figure 7 showing the most
common response to either a written description or enablement rejection are claim
amendments).
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their structure (instead of their antigen) suggests a much narrower
antibody claim today compared to 2002.
We show that applicants are obtaining more and more
antibody patents over time, we find a five-fold increase in antibody
patents over the course of this seventeen-year period. Of course, this
correlates with the ever-increasing importance of biologics as
therapeutics. Although applicants are filing more patents, there are
fewer claims per patent and those claims are much narrower in
scope.
Additionally, we find that more and more of these patents are
coming from the same family of patents as outlined by the ten-fold
increase in ODP rejections, which can only be used against patents
within the same family (Table 2).51 These data argue that many of
these patents are directed to the same antibody product or have
relevant family members.
Similar to putting together a jigsaw puzzle with only half the
pieces, firms could be cobbling together many narrow patents to try
and achieve the same broad patent scope that they were previously
able to attain with one genus patent.52 See, for example the Humira
family of patents, which purportedly contains over 150 patents
covering similar products.53 Many of these patents contain
antibodies that have been defined by different CRDs or by their
heavy and light chain framework regions.
51

A patent in the “same family” would be defined by the presence of an ODP rejection
which requires: (1) a common inventor or owner and (2) the application at issue must be
obvious in view of the subject matter claimed and (3) no restriction requirement that resulted
in the subject matter at issue being pursued in a separate divisional application. See MPEP
§804.
52
See for example the Humira Patent family with over 100 associated patents. See also
Jeffrey Wu & Claire Wan-Chiung Cheng, Into the Woods: A Biologic Patent Thicket
Analysis, 19 Chicago Kent J. Intell. Prop 93, 130. (2021) and Rachel Moodie and Bernard
Chao, Biological Patent Thickets and Delayed Market Access to Biosimilars, An American
Problem, (2022, in manuscript).
53
See for example Humira patents: U.S. 8,414,894 (claim 61, 68, 76, defining both the
LCVR and HCVR); and U.S. 8,372,401 (claim 1 defining an almost complete heavy and
light chain region). See also Jeffrey Wu & Claire Wan-Chiung Cheng, Into the Woods: A
Biologic Patent Thicket Analysis, 19 Chicago Kent J. Intell. Prop 93, 130. (2021)(Table 5,
finding more than 154 patents associated with the Humira antibody product). Rachel Moodie
and Bernard Chao, Biological Patent Thickets and Delayed Market Access to Biosimilars,
An American Problem, (2022, in manuscript).
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Some commentator have expressed concern that large patent
thickets have delayed biosimilar market entry.54 Others argue that
the pendulum has swung too far, and that applicants are now
inappropriately being denied genus claims.55 It is possible that
innovators have responded to the narrowing scope of antibody
patents by obtaining a larger number of patents with relatively
narrow claims.
D. Speeding Up Prosecution
In 2002, antibody patents took about 30 months to go through
prosecution, but that time has been reduced to only 14 months in
2018.56 Correspondingly, the number of office actions required to
obtain a patent was also cut in half over this seventeen-year period.
The overall patent pendency at the PTO has decreased from 31
months to about 24 months since 2013. In contrast, there is an
increase in pendency from 23 to 25 months for patents in TC 1600
over the past two years.57 Thus, antibody patents seem to be moving
through the patent office much faster than other patents.58
Thus, the back-and-forth negotiations between the examiner
and the applicant for antibody patents are far fewer now than two
decades ago. This could be because the claims are much narrower
and thus require fewer limitations since applicants have already
started with antibody claims that give structure and are narrower in
scope. Additionally, these data suggest that both applicants and
examiners understand what is required to overcome the written
54
Rachel Moodie and Bernard Chao, Biological Patent Thickets and Delayed Market
Access to Biosimilars, An American Problem, (2022, in manuscript)(Figure 1 showing that
the US biologic market creates large patent thickets. Where the US asserts 377 patents
covering 30 biosimilars, Canada and the United Kingdom only assert 46 and 24, respectively
for those same 30 biosimilars); see also Jeffrey Wu & Claire Wan-Chiung Cheng, Into the
Woods: A Biologic Patent Thicket Analysis, 19 Chicago Kent J. Intell. Prop 93. (2021)
55
Dmitry Karshtedt, Mark A. Lemley, and Sean B. Seymore, The Death of the Genus
Claim, 35 Harvard Journal of Law and Technology (2022, forthcoming). Cf. Christopher M.
Holman, Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part I,
Biotechnology Law Report (in manuscript, 2022).
56
See Figure 10 above.
57
See https://www.uspto.gov/dashboard/patents/total-pendency-by-tc.html
58
We note that the 1650 control group also exhibited a decrease in prosecution time
from approximately 24 to 18 months. However, this decrease is significantly less than the
16 month decrease from 30 to 14 months exhibited for antibody patents.
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description and enablement standards. In contrast, the earlier
patents filed in the early 2000’s had broad scope and likely needed
more rounds of prosecution to narrow the scope of the claims.59
These data also show that antibody patents receive fewer
anticipation and obviousness rejections.60 It is likely that we see
fewer prior art rejections because these very narrow claims are truly
novel and non-obvious over the prior art, especially if they contain
both structural and functional requirements. Typically, anticipation
and obviousness rejections based on prior art are the most difficult
and time consuming to overcome.61 Thus, patent claims that do not
face these rejections can move through prosecution faster.
IV. IMPROVING ANTIBODY PATENT PROSECUTION62
Antibody technology has radically advanced within the last
30 years. Revolutionary changes in antibody technology have
moved antibodies from research tools to diagnosis to treatment of
diseases. Current antibody technology now allows researchers to
create consistent and highly specific antibodies that can not only
treat diseases, but treat disease without many of the key side effects
previously common to these drugs. While the uses for antibodies
have increased, the numbers of patents filed towards antibodies
have commensurately increased. Courts, the USPTO administration
and patent examiners have all responded. Interestingly, however,
they have not all moved in the same direction at the same pace.
The USPTO administration, patent examiners, and courts
have all taken notice of these scientific advances and have
significantly limited the scope of these patents by using the written
description and enablement requirements, thus forcing applicants to
specifically describe their invention by giving structural elements to
the claimed antibody. The Federal Circuit is willing to invalidate
59

See Figure 2 and Section III(C) supra.
See Table 1(showing that the 1650 control group exhibits more than two fold more
obviousness rejections) and Figure 4 (showing that 103 rejections comprise less than 10% of
the rejections experienced by antibody patents are obviousness rejections, while most other
inventions receive seven times more obviousness rejections).
61
S. Sean Tu, Patenting Fast and Slow: Examiner and Applicant Use of Prior Art, 38
Cardozo Arts and Entertainment Law Journal 101 (2020).
62
S. Sean Tu, is the sole author of Section IV. Christopher Holman does not concur
with the recommendations proposed in this section.
60
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patents and reverse billion-dollar judgements based on the written
description and enablement requirements.63 The courts and the
USPTO administration, however, have been slow to implement
change in response to the changes to antibody technology. In
contrast, patent examiners have been actively rejecting patents based
on these theories for over a decade.
A. Allow Science to Guide the Law
Interestingly, patent examiners applied these enhanced
patentability rules for written description and enablement
independent of court cases or even in the face of the USPTO written
description rules that would otherwise allow broad patent claims.
Specifically, patent examiners were forcing applicants to disclose
structural features (and not just describing the antigen) before many
changes in the caselaw and even after the 2008 USPTO written
description guidelines that specifically stated that antibody claims
based on antigen structure alone could satisfy the written
description requirement.
This phenomenon is most likely due to the fact that most
patent examiners in this technology center are highly educated
scientists64 and although they do apply the legal rules for
patentability, they do so through the lens of a scientist. Patent
examiners, therefore, are the most in tune with changes in
technology.
Most patent examiners in this technology center, however, do
not have a law degree.65 Patent examiners are also unlikely to be in
63

See Centocor Ortho Biotech, Inc. v. Abbott Lab’ys, 636 F.3d 1341 (Fed. Cir. 2011)
(where the Federal Circuit overturned a $1.67 billion dollar verdict and invalidated a set of
patents based on the lack of written description); Juno Therapeutics Inc. v. Kite Pharma,
Inc., No. 20-1758 (Fed. Cir. 2021)(where the Federal Circuit reversed a $1.2 billion dollar
verdict and invalidated a patent based on lack of written description); Amgen Inc. v. Sanofi,
987 F.3d 1080 (Fed. Circ. 2021)(where the Federal Circuit affirmed invalidation of a set of
patents based on the enablement requirements);
64
S. Sean Tu, Paul Gugliuzza, and Amy Semset, Overqualified and Underrepresented:
Gender Inequality in the Pharmaceutical Patent Field (2021, in manuscript)(Table 2,
showing that over 50% of examiners have a Ph.D.)
65
S. Sean Tu, Paul Gugliuzza, and Amy Semset, Overqualified and Underrepresented:
Gender Inequality in the Pharmaceutical Patent Field (2021, in manuscript)(Table 2,
showing that the only about 15% of patent examiners in TC1600 have a J.D.)
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tune with the most current changes to patent law jurisprudence.
Accordingly, it is somewhat unsurprising that patent examiners
have been applying a stricter written description and enablement
standard than courts for over a decade. What is surprising is that
they have largely ignored the USPTO’s own 2008 written description
guidelines that specifically allow broad antibody claims based solely
on antigen structure.66 In the early days of antibody technology,
these broad antigen defined antibody claims were allowable. After
Lilly, it looked like antibody patents would be narrowed much like
many other biotechnology inventions.67 However, the courts and the
PTO carved out an exception for antibodies, which allowed them
broader scope. The courts, however, have now caught up with what
patent examiners have been doing for a decade, that is using the
written description requirements to narrow antibody claims.
Denying broad antibody claims while allowing narrower
antibody claims has produced robust growth in the antibody field.
Ultimately, patent examiners help innovators by denying claims that
would subsequently be struck down in court. Rejecting these patents
spares investors from spending resources based on these patents.
Additionally, this creates more certainty, predictability and
confidence for investors.
By allowing narrower claims patent law strikes a balance
between granting exclusive rights to what the inventor disclosed to
the public while protecting against overly broad claims that may
hinder innovation in the area. Additionally, unlike broad genus type
patents, narrow patent rights incentivizes competitors to “design
around” products to create additional novel therapeutic antibodies
(even if they are directed towards the same antigen).
B. Reverse Doctrine of Equivalents
Patent law attempts to promote the progress of science by
giving limited exclusive rights to inventors. This is a delicate
66

Written Description Training Material, Revision 1, March 25, 2008. (Example 13,
showing that a claim directed towards “An isolated antibody capable of binding to antigen
X” can satisfy the written description requirements of 35 U.S.C. §112).
67
Christopher M. Holman, Is Lilly Written Description a Paper Tiger: A comprehensive
Assessment of the Impact of Eli Lilly and Its Progeny in the Courts and PTO, 17 Alb. L.J.
Sci. & Tech. 1 (2007).
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balance for the biologics field. On one hand it may be necessary to
provide broader patent protection to motivate firms to take the risk
to innovate in this technology, which requires high up front costs.68
On the other hand, giving too much protection can inhibit
innovation by providing important follow on technology. Some
commentators have argued that the pendulum has swung too far
arguing that applicants are now inappropriately being denied genus
claims.69
One solution to this delicate balance may lie in the rarely used
Reverse Doctrine of Equivalents (reverse DOE). The reverse DOE
allows improvers to capture the value associated with an invention
that would literally infringe another’s patent. Accordingly, the
reverse DOE could offer a solution to reward improvers even though
their improvements would literally infringe on a prior patent.70
The rarely used reverse DOE is a mechanism by which a court
can find that an invention does not actually infringe on a patent even
though it literally falls within the scope of the claims.71 The original
example of reverse DOE occurred in 1869 when George
Westinghouse invented a train brake that used compressed air from
a central reservoir to stop the train. In 1887 George Boyden
improved on this break by using compressed air from a central
reservoir and a local reservoir in each brake cylinder. The Supreme
68

Olivier J. Wouters, Martin McKee, Jeroen Luyten, Estimated Research and
Development Investment Needed to Bring a New Medicine to Market, 2009-2018, 323 JAMA
844 (2020) (showing that the median capitalized research and development investment to
bring a new drug to market was estimated at $985.3 million).
69
Dmitry Karshtedt, Mark A. Lemley, and Sean B. Seymore, The Death of the Genus
Claim, 35 Harvard Journal of Law and Technology (2022, forthcoming). Cf. Christopher M.
Holman, Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part I,
Biotechnology Law Report (in manuscript, 2022).
70
Scripps Clinic & Research Found. v. Genetech, Inc., 927 F.2d 1565, 1581 (Fed. Cir
1991) (suggesting that a device may escape liability under the reverse doctrine of equivalents
because it is a radical improvement over the patented technology); Atlas Power Co. v. E.I.
duPont de Nemours & Co., 750 F.2d 1569 (Fed. Cir. 1984). See also Robert Merges,
Intellectual Property Rights and Bargaining Breakdown: The Case of Blocking Patents, 62
Tenn. L. Rev. 75 (1994); Robert P. Merges, A Brief Note on Blocking Patents and Reverse
Equivalents: Biotechnology as an Example, 73 J. Pat. & Trademark Off. Soc’y 878 (1991).
71
Ethyl Molded Prods. Co. v. Betts Package, Inc., 9 U.S.P.Q.2d 1001, 1026 (E.D.Ky.
1988) (stating that, “the reverse doctrine of equivalents, although frequently argued by
infringers, has never been applied by the Federal Circuit.”); see also Robert P. Merges, A
Brief Note on Blocking Patents and Reverse Equivalents: Biotechnology as an Example, 73
J. Pat. & Trademark Off. Soc’y 878, 884 (1991)
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Court found that, the new invention “has so far changed the
principle of the device that the claims of the patent, literally
construed, have ceased to represent his actual invention.”72
Similarly, the Court in Graver Tank stated that:
[W]here a device is so far changed in principle from a
patented article that it performs the same or similar
function in a substantially different way, but
nevertheless falls within the literal words of the claim,
the [reverse] doctrine of equivalents may be used to
restrict the claim and defeat the patentee’s action for
infringement.73
As outlined by Merges, reverse DOE may be especially
justified when the original patent contributes very little value
compared to the improvement.74 When the improvement greatly
increases the value of the original patent, then an inefficient holdup
problem may become significant. The social costs of this holdup
problem is also significant because the improvement must “sit on the
shelf for the life of the original patent.”75 Reverse DOE solves this
problem by excusing the improver from infringement liability, thus
preventing the patentee’s holdup right.76
Reverse DOE may be a suitable response to the current
situation where courts and the PTO only allow very narrow
antibody claims. In calculating the balance between broad and
narrow rights, we could default to allowing broad patents and then
use reverse DOE to excuse liability for those follow on inventions
that greatly increase the value of the original patent.
We may want to create a system where we initially give broad
protection for novel inventions based on antibody technology then
use the reverse DOE to exclude follow-on technology that greatly
72

Westinghouse v. Boyden Power-Break Co., 170 U.S. 537, 562 (1898).
Graver Tank & Mgf. Co. v. Linde Air Prods. Co., 399 U.S. 605, 608-09 (1950).
74
Robert P. Merges, A Brief Note on Blocking Patents and Reverse Equivalents:
Biotechnology as an Example, 73 J. Pat. & Trademark Off. Soc’y 878, 885 (1991).
75
Robert P. Merges, A Brief Note on Blocking Patents and Reverse Equivalents:
Biotechnology as an Example, 73 J. Pat. & Trademark Off. Soc’y 878, 886 (1991).
76
Robert P. Merges, A Brief Note on Blocking Patents and Reverse Equivalents:
Biotechnology as an Example, 73 J. Pat. & Trademark Off. Soc’y 878, 886 (1991).
73
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differs from the patented invention. Specifically, courts might use
the reverse DOE in a case where a humanized or chimeric antibody
that recognizes a different epitope or has significantly different
functional characteristics from the patented antibody.
One possible application of this solution could be exemplified
by the AbbVie case.77 The AbbVie court held two AbbVie patents
invalid because they lacked adequate written description. These
patents were directed to fully human antibodies that bind to and
neutralize the activity of human interleukin 12 (IL-12). AbbVie
obtained a broad patent directed to fully human anti-IL-12
antibodies.78 Although the AbbVie patents broadly claimed full
human IL-12 antibodies, all of the disclosed AbbVie antibodies had:
(1) VH3 heavy chains, (2) lambda light chains, (3) at least 90%
similarity with Joe-9 in variable regions and (4) more than 99.5%
similarity in variable regions.
Centocor produced Stelara (ustekinumab) which was a fully
human IL-12 antibody that neutralized the activity of IL-12. Stelara
literally infringed the AbbVie patent. However, Stelara was
structurally distinct from Joe and Joe-derived antibodies. Table 4
outlines these key differences.
Table 4
Sequence Similarity
CDR Length
Epitope Binding
Site
VH Family
Light Chain Type

Stelara
50%
Different
Side
Binder
VH 5
Kappa

J695
90%
Identical
Bottom
Binder
VH 3
Lambda

Joe-9
90%
Identical
Bottom
Binder
VH 3
Lambda

Instead of invalidating the AbbVie patents based on lack of
written description, a court could have held the patents valid, but
77

Abbvie Deutschland GMBH & Co, v. Janssen Biotech, Inc., 759 F.3d 1285 (Fed. Cir.

2014).
78

U.S. Pat. No. 6,914,128 and 7,504,485 (exemplary claim 29 of the ‘128 patent reads,
“A neutralizing isolated human antibody, or antigen-binding portion thereof that binds to
human IL-12 and dissociates from human IL-12 with a Koff rate constant of 1x10-2s-1 or less,
as determined by surface plasmon resonance.”)
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excused Centocor from liability under the reverse DOE. Excusing
liability under the reverse DOE in this case is rational because the
Stelara antibody improvements changed the principle of the device
in a way that no longer represented what AbbVie disclosed in the
specification of their patents.
Allowing broad claims while carving out exceptions to those
broad claims by using reverse DOE, however, is not a magic bullet.
Reverse DOE is an ex post solution applied by courts only after heavy
investment in the technology by competitors. Thus, reverse DOE
does not address the incentives issue because competitors would not
know ex ante if their antibody is “too similar” to the patented
antibody. Accordingly, a rational competitor might simply avoid the
risk of infringing a broad patent by never investing in research on
new antibodies in the first place.
Additionally, if reverse DOE is applied too narrowly, then it
would act identically to the current written description and
enablement framework. Specifically, if reverse DOE is interpreted to
only grant a scope exactly commensurate with those working
examples disclosed in the specification, then it is no better than using
the current written description and enablement standards.
Conclusions
Courts, the PTO administration, and patent examiners have
all dealt with antibody patents in slightly different ways. However,
it seems that all three arms have now reached a consensus. Each
group is now using 112(a) to deny broad claims based only on
function and antigen structure. However, narrow claims with
antibody structural elements are currently allowed.
This study shows that patent examiners over time have
increasingly used 112(a) rejections to narrow claims. Antibody
patents moved from broad functional claims to narrow structurally
limited claims. Finally, an increase in the number of words per
independent claim and the increased use of continuation practice
combined with shorter prosecution durations all suggest that the
scope of antibody patents has narrowed over time.
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Appendix 1- Antibody Fundamentals
A. General Definitions

1. Antigen- the target molecule that the antibody binds to.
2. Epitope- the specific region of an antigen that the antibody binds to.
3. Paratope- The region of an antibody that is responsible for binding
to the epitope.
4. Complementarity Determining Regions (CDRs)- six regions on the
antibody that collectively come into contact with the antigen. There
are three CDR loops per variable domain in antibodies (three on the
light chain and three on the heavy chain). CDRs on the light chain
are labeled CDR L1, CRD L2 and CDR L3. CDRs on the heavy
chain are labeled CDR H1, CRD H2 and CDR H3.
5. Light Chain / Heavy Chain- Antibodies are comprised of two light
chains and two heavy chains in a Y-structure shown in Figure X.
Each Y contains two identical copies of a heavy chain and two
identical copies of a light chain which are different in their sequence
and length. The top of the Y shape is defined by the CDR
sequences which form the paratope, which binds tightly and
specifically to an epitope on the antigen.
6. Variable region- the region defined byt eh CDRs and surrounding
framework regions.
7. Constant region- the part of an antibody that is common to its
particular class. The constant region is involved in triggering the
immune response and determines the mechanism by which the
antigen is destroyed.
8. Polyclonal Antibody- a diverse population of antibodies targeted to
the same antigen.
9. Monoclonal Antibody- a single antibody directed to a target
epitope.
10. Bispecific Antibody- an antibody that can bind two targets.
11. Chimeric Antibody- An antibody that has been engineered from
more than one different species. Commonly, the variable region is
defined by a non-human antibody which is then linked to the
constant region of a human antibody. This is done to limit the
human immune response to a mouse antibody.
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12. Humanized antibody- A subclass of chimeric antibody where most
of the sequences are human in origin.
B. Antibody Structure, Function and Method of Production

Antibodies, also known as immunoglobulins, are natural
products of the body that are secreted by B-cells as part of an
immunological response to neutralize antigens such as bacteria and
viruses. The structure of an antibody is shown in Figure 1. The
antibody structure is a classic Y-shaped molecule composed of two
heavy chains (connected by a linker) and two light chains (connected
to the heavy chains). Each tip of the “Y” contains a paratope which
can bind only one epitope on an antigen. This allows the antibody to
bind its antigen with precision. There are two main types of
antibodies: polyclonal and monoclonal. Monoclonal antibodies are
identical and have the same binding specificity and recognize the
same epitope. In contrast polyclonal antibodies against an antigen
are a mixture of molecules having different binding sites, different
binding specificities and typically recognize different epitopes on the
antigen.
Figure 1
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Polyclonal antibodies (pAbs) are a mixture of heterogenous
antibodies which are usually produced. By different B cell clines in
the body. Thus, pAbs recognize and bind to many different epitopes
of a single antigen. Polyclonal antibodies are usually generated by
injecting an animal with an antigen. After injection, the animal
elicits a primary immune response, and then given a secondary
injection (and sometimes a third injection) to boost the immune
response. The serum79 can then be collected and polyclonal
antibodies to the antigen can then be isolated using an immobilized
antigen.
There are several benefits associated with pAbs. First, is the
relative ease and cost of production of pAbs. pAbs are highly stable
and can tolerate pH or buffer changes. pAbs bind more than one
epitope and can help amplify the signal from a target protein even
with low expression levels. Accordingly, pAbs are ideal for
immunoprecipitation and chromatin immunoprecipitation. Finally,
pAbs are less sensitive to antigen changes such as denaturation,
polymorphisms and different glycosylation patterns. One major
downside to pAbs, however, is the fact that there is batch to batch
variability because each animal will mount a different immune
response to the antigen injection. Polyclonal antibodies have been
used as components of antivenom, antitoxin, and transplant
antirejection drugs. Importantly pAbs are also used to detect disease
in blood or tissue samples. For examples, pAbs have been used to
detect for viruses, cancers, encephalitis, HIV and Lyme disease.
Monoclonal antibodies (mAbs) revolutionized antibody
technology. In contrast to pAbs, mAbs are usually not produced in
live animals. In 1975, Nobel laureates Kohler and Milstein produced
the first mAbs.80 Monoclonal antibodies are generated using
hybridoma technology, which is a product of splenocyte and
myeloma cell fusions creating an immortalized B-cell-myeloma
hybridoma. The hybridomas are able to grown continuously in
culture while producing antibodies. These antibodies are then
79

Serum consists of blood where the clotting proteins and red blood cells are
removed.
80
George Kohler and Cesar Milstein, Continuous cultures of fused cells secreting
antibody of predefined specificity, 256 Nature 495 (1975). George Kohler and Cesar Milstein
shared the 1984 Nobel prize in medicine for this breakthrough.
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screened for the desired mAbs. Importantly, monoclonal antibodies
exhibit precise and reproducible binding properties. Monoclonal
antibodies bind one specific epitope on an antigen.
Figure 2A describes the different binding specificities of mAbs
compared to pAbs. Polyclonal antibodies have the ability to bind
different epitopes (triangles and rectangles) on the same antigen. In
contrast, mAbs can bind only one specific epitope (triangles) on an
antigen. Figure 2B shows that polyclonal antibodies bind to multiple
epitopes on the same antigen, while monoclonal antibodies can bind
to only one epitope.
Figure 2A

Figure 2B
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The benefits of using mAbs cannot be understated. First,
mAbs are highly specific and recognize only one epitope of an
antigen. Second, once an immortal hybridoma cell line is created,
the firm has the ability to produce unlimited quantities of the mAb.
Because mAbs recognize only one epitope, the results of mAbs are
highly consistent with minimal background noise and crossreactivity. However, the cost and time needed to generate
monoclonal antibodies is considerably greater than polyclonal
antibodies. Additionally, it takes a much longer amount of time and
requires highly technical knowledge to create these hybridomas.
Additionally, mAbs are vulnerable to changes in the epitope and
even small changes in antigen conformation may lead to
dramatically reduced binding capacity. Due to these consistent
results, mAbs are much better suited to be used for therapeutic
treatments. Accordingly, mAbs have been used to treat diseases such
as rheumatoid arthritis81, asthma82, psoriasis83 and many forms of
cancer84.
81
Adalimumab (Humira) from Abbvie is a fully human antibody against TNF used to
treat rheumatoid arthritis.
82
Dupilumab (Dupixent) from Regeneron Pharmaceuticals is a fully human antibody
against IL4RA used to treat atopic dermatitis and asthma.
83
Infliximab (Remicade) from Centocor is a chimeric antibody against TNF that is used
to treat Chron’s disease and plaque psoriasis.
84
Atezolizumab (Tecentriq) from Genentech is a humanized antibody against PD-L1that
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Monoclonal antibodies produced using mouse hybrdiomas
are not ideal for use as human therapeutics. This is because humans
injected with mouse mAbs will mount an immune response because
the human body will recognize the mouse mAb as foreign and
attempt to remove it from the body. This response is known as the
Human Anti-Mouse Antibody (HAMA) response, and occurs when
the human immune system recognizes the mouse antibody as
foreign and attack it. A HAMA response can cause toxic shock or
even death in a patient. Additionally, most mouse mAbs suffer from
a short serum half-life in humans.
Accordingly, additional steps are required for mAbs that will
be used for treatment of disease in humans. Monoclonal antibodies
must be “humanized” for human clinical use. Figure 3 shows the
humanized and chimeric versions compared to mouse antibodies.
Chimeric and humanized antibodies reduce the likelihood of a
HAMA response by minimizing the non-human portions of
administered antibodies. Thus, because most regions of the chimeric
and humanized antibodies are human, these antibodies do not elicit
as much of an immune response from the patient. Furthermore,
chimeric and humanized antibodies have the additional benefit of
activating secondary human immune responses such as antibody
dependent cellular cytotoxicity. Furthermore, these chimeric /
humanized antibodies have a much longer serum half-life.
Chimeric antibodies are created by substituting the mouse
constant region with a human constant region. Thus, the chimeric
antibody consists mainly of a human constant region with only the
variable regions of the antibody of mouse origin.
Humanized mAbs are created through genetically
engineering the mouse B-cell so that the variable regions of the
mouse light and heavy chain genes are ligated to human constant
regions. This creates an antibody that most of the mouse sequence
has been replaced with human Ig sequence. This process results in
is used to treat Urothelial carcinoma and metastatic non-small cell lung cancer; Bevacizumab
(Avastin) from Genentech is a humanized antibody against vEGF used to treat metastatic
colorectal cancer; Pembrolizumab (Keytruda) from Merck is a humanized antibody against
PD-1 that is used to treat metastatic melanoma; Rituximab (Rituxan) from Genentech is a
chimeric antibody against CD20 that is used to treat B-cell non-Hodgkin’s lymphoma.
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the production of a mAb that is mostly “human” with only the
antigen binding site being of mouse origin. Because the mAb is
mostly human in origin, the patient does not recognize the
humanized mAb as foreign and does not generate large quantities of
anti-mAb antibodies that would hinder the therapeutic mAb’s
effectiveness.
One of the newest antibody technologies involve use of a phage
display library to artificially construct soluble Fab fragments. These
Fab fragments have the ability to penetrate tissues efficiently and do
not need to be processed through the endoplasmic reticulum.
However, one major drawback to this approach is that a new phage
library must be constructed for every antigen, which is a timeconsuming process. Additionally, Fabs are not full-length antibodies
and lack the C region which is responsible for effector functions.
Additionally, Fabs are produced in bacteria and therefore are not
glycosylated, which leads to a much shorter half-life.
Finally, mAbs are being produced in plants for use in humans.
These “plantibodies” are full length antibodies that are glycosylated
and thus have a longer half-life in the patient’s body. Plantibodies
are generated by creating a transgenic plant that express human
mAbs without harming their own metabolism. Accordingly, large
quantities of human mAb can be created cheaply and the seeds
produced by these plants can be easily stored.
Figure 3

Electronic copy available at: https://ssrn.com/abstract=4025167

46

Orange Book Patent Prosecution and Litigation

[2-Feb-22

Electronic copy available at: https://ssrn.com/abstract=4025167

